Five Top Health Care Names From RBC to Buy Now
ThinkstockThe intense analysis of quantitative managers may seem like drudgery, but it can turn up absolute gems for investors looking for solid long ideas. In fact, firms like RBC use as much as 18…
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 290Merck Earnings Mixed as Drug Sales Slow
Merck & Co. reported mixed first-quarter 2014 results before markets opened Tuesday morning. The loss of market exclusivity continues to hurt the top line. Merck reaffirmed its forecast for the full year.
America’s Most (and Least) Healthy Cities
ThinkstockThere’s no doubt that great strides have been made in Americans’ health over the years. Americans smoke less, are more likely to be insured and live longer. However, significant health disparities remain across the…
Meda Shareholder Blocks Mylan’s Second Takeover Bid
Shares of Mylan retreated first thing Monday morning, after the generic drugmaker's sweetened bid for Swedish drugmaker Meda was rejected.
Biotech: The Poster Child for Market Volatility in 2014
The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5. It jumped 23% over the next three weeks, and then gave it all back…
Expired Patents Take a Bite out of Eli Lilly Results
Eli Lilly reported disappointing first-quarter 2014 results before markets opened Thursday, due in part to the impact of U.S. patent expirations for Cymbalta and Evista. Shares were up in premarket trading.
Why Investors Are Not Chasing Gilead Endlessly Higher
ThinkstockBy any stretch of normal measurement in earnings season, Gilead Sciences Inc. (NASDAQ: GILD) should have been a rocketing stock on Wednesday. Gilead blew away earnings and revenue estimates. Its Sovaldi Hepatitis C drug…
Lombard Signals More Evidence of IPO Market Reality Check
The market for initial public offerings was getting to be a bit ridiculous. Now that volatility has returned in the broader stock market, a reality check is starting to be seen as more IPOs…
Companies Betting on the Next 10 Blockbuster Drugs
24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in hand, while others have pending FDA approval verdicts.
UBS Top Stocks to Buy Working for Cancer Cures
In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are making major advances in cancer therapeutics. Here is the UBS list of stocks that…
An Earnings Tale of Two Biotechs: Gilead vs. Amgen
ThinkstockGilead Sciences Inc. (NASDAQ: GILD) and Amgen Inc. (NASDAQ: AMGN) have both reported earnings. This is a definite difference in how the reports look, and it could throw a wild card report for the…
Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene
ThinkstockBiotech stocks took it on the chin during the sell-off. In fact, biotech stocks may have even led the sell-off of momentum stocks in a reality check. The problem is that after years of…
GW Pharma Dual Cannabinoid Endorsement: Morgan Stanley and Jim Cramer
GW Pharmaceuticals is far from your typical pharma or biotech stock. It is also far from your typical legalized marijuana or medical marijuana stock. And shares surged on a pair of endorsements.
Jefferies Initiates Coverage on Specialty Pharmaceutical Takeover Candidates
The specialty pharmaceutical sector is exploding with news of takeovers, exchanges and possible mergers. Here are some of the top stocks started with a rating of Buy at Jefferies.
What a Combined Pfizer and AstraZeneca Would Look Like, and Face
ThinkstockIt is not that common that you hear about mergers in the $50 billion range. But what about when you hear of mergers in the $80 billion or $100 billion range? AstraZeneca PLC (NYSE:…